未登录

F

Fangfang Xu

Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology

H指数:7

被引数:147

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrating necroptosis and immune landscapes: a multi-omics-derived NecropImmScore stratifies prognosis and therapy in ovarian cancer

整合坏死性凋亡和免疫景观：一种多组学衍生的NecropImmScore可对卵巢癌进行预后分层和治疗方案选择

Cancer Immunology, Immunotherapy

IF0

2025-10-150

OA

Decoding adenomyosis pathogenesis using an assembloid model

使用组装体模型解码腺肌症发病机制

science china life sciences

IF0

2025-08-280

PRE

Activation of α7 Nicotinic Acetylcholine Receptors Inhibits Hepatic Necroptosis and Ameliorates Acute Liver Injury in Mice

IF9.1

2024-08-260

PRE

Transplantation of the LRP1high subpopulation of human umbilical cord-derived mesenchymal stem cells improves ovarian function in mice with premature ovarian failure and aged mice

STEM CELL RESEARCH & THERAPY

IF7.3

2024-03-052

OAAI

Dual Role of Necroptosis in Cervical Cancer: Promoting Tumor Aggression and Modulating the Immune Microenvironment via the JAK2-STAT3 Pathway

坏死性凋亡在宫颈癌中的双重作用: 通过JAK2-STAT3途径促进肿瘤攻击和调节免疫微环境

JOURNAL OF CANCER

IF3.2

2024-01-011

OAAI

Comprehensive analyses identify RIPOR2 as a genomic instability-associated immune prognostic biomarker in cervical cancer

综合分析确定RIPOR2是宫颈癌中基因组不稳定性相关的免疫预后生物标志物

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-08-269

OAAI

Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer

FRONTIERS IN IMMUNOLOGY

IF5.9

2021-10-2113

OAAI